 NEW YORK, May 26, 2021 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today announced that clinical data related to REL-1017, the companys lead product candidate, will be presented in a live oral poster presentation at the 2021 American Society of Clinical Psychopharmacology ASCP Annual Meeting, which is being held virtually between June 1 and June 4, 2021. Details of the virtual oral presentation are as follows: Title: REL-1017 esmethadone is Safe, Well-Tolerated and Exerts Rapid, Robust and Sustained Antidepressant Effects as Adjunctive Treatment in Patients with Major Depressive Disorder: a Phase 2 Double Blind Randomized Trial Presenter: Marco Pappagallo, MD, Chief Medical Officer of Relmada Therapeutics Session Title: Pharmaceutical Pipeline Session Date and Time: Tuesday, June 1, 2021, from 2:45 4:45 PM ET About REL-1017 REL-1017, a novel NMDA receptor NMDAR channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development as an adjunctive treatment for MDD in adults. 